Related Experiment Videos
Modeling partially effective HIV vaccines in vitro
Rohan John1, Silvio Arango-Jaramillo, Steve Self
1Department of Molecular Microbiology and Immunology, The Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA.
The Journal of Infectious Diseases
|February 10, 2004
Summary
A new in vitro challenge assay (IVCA) measures human immunodeficiency virus (HIV) net antiviral effects. This assay can identify subtle differences in vaccine effectiveness, aiding the selection of promising HIV vaccine candidates for trials.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- Incompletely effective human immunodeficiency virus (HIV) vaccines can offer public health benefits.
- Standard immunogenicity assays may not correlate with HIV vaccine antiviral effectiveness or detect subtle effects.
Purpose of the Study:
- To develop and validate an in vitro challenge assay (IVCA) for measuring net antiviral effects against HIV.
- To model partially effective postvaccination immune status to assess assay sensitivity.
Main Methods:
- Developed an IVCA using peripheral blood mononuclear cells (PBMCs) to assess net antiviral effect against any HIV isolate.
- Modeled partial vaccine effectiveness through four distinct approaches: using PBMCs from exposed uninfected individuals, CD8+ cell manipulation, chemokine blocking, and varying challenge virus dose.
Main Results:
- The IVCA demonstrated sensitivity in detecting as little as 3-fold differences in challenge titer (30, 10, and 3 50% tissue-culture infective doses).
- The assay could also detect differences in the odds ratio of HIV infection, indicating robustness.
Conclusions:
- The developed IVCA is a robust and simple assay for measuring net antiviral effects in whole blood.
- This assay is valuable for evaluating HIV vaccine candidates and identifying those suitable for efficacy trials.